In May 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Lumakras (sotorasib, AMG-510), a targeted anticancer drug, for the treatment of NSCLC patients with a KRASG12C mutation.52 It also became the first targeted drug for the treatment of KRAS gene mutation in the world, breaking the “undruggable” dilemma and marking a milestone in medical history. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.